RSS-Feed abonnieren
DOI: 10.1055/s-2003-36665
Chronisch-aktiver Morbus Crohn
Chronically Active Crohn's DiseasePublikationsverlauf
Publikationsdatum:
16. Januar 2003 (online)

Die Analyse der Studien zum chronisch aktiven Verlauf ist erschwert durch eine fehlende verbindliche und damit meist sehr variable Definition des chronisch aktiven Verlaufs. Ebenso ist eine Abgrenzung zu Studien zur Remissionserhaltung oft nicht möglich. Für zukünftige Studien ist daher eine international verbindliche Definition anzustreben.
Völlig ungeklärt ist die Frage, inwieweit eine initiale aggressive Immunsuppression bei M. Crohn den weiteren Verlauf günstig beeinflusst. Neue immunsuppressive Therapieansätze wie z. B. 6-Thioguanin oder Cyclophosphamid sind Gegenstand laufender Untersuchungen und sollten derzeit außerhalb von Studien nicht zum Einsatz kommen.
Bezüglich des Nebenwirkungsprofils von Immunsuppressiva liegen umfangreiche Erfahrungen auch aus anderen Fachgebieten (z. B. Rheumatologie) vor. Leitlinien aus diesen Bereichen haben, soweit sinnvoll, Eingang in die Empfehlungen zur Überwachung der Therapie des chronisch aktiven Verlaufes des M. Crohn gefunden.
Literatur
- 1
Wright J P, Young G O, Tigler Wybrandi N.
Predictors of acute relapse of Crohn’s disease. A
laboratory and clinical study.
Dig Dis Sci.
1987;
32
164-170 (III)
Reference Ris Wihthout Link
- 2
Sandborn W, Sutherland L, Pearson D. et al .
Azathioprine or 6-mercaptopurine for inducing remission of
Crohn’s disease.
Cochrane Database Syst Rev.
2000;
2 (Ia)
Reference Ris Wihthout Link
- 3
Pearson D C, May G R, Fick G. et al .
Azathioprine for maintaining remission of Crohn’s
disease.
Cochrane Database Syst Rev.
2000;
2 (Ia)
Reference Ris Wihthout Link
- 4
Feagan B G, Rochon J, Fedorak R N. et al .
Methotrexate for the treatment of Crohn’s disease. The
North American Crohn’s Study Group Investigators.
N Engl J Med.
1995;
332 (5)
292-297 (Ib)
Reference Ris Wihthout Link
- 5
Mate-Jimenez J, Hermida C, Cantero-Perona J. et al .
6-mercaptopurine or methotrexate added to prednisone induces
and maintains remission in steroid-dependent inflammatory bowel disease.
Eur J Gastroenterol Hepatol.
2000;
12 (11)
1227-1233 (Ib)
Reference Ris Wihthout Link
- 6
Stack W A, Mann S D, Roy A J. et al .
Randomised controlled trial of CDP571 antibody to tumour
necrosis factor-alpha in Crohn’s disease.
Lancet.
1997;
349 (9051)
521-524 (Ib)
Reference Ris Wihthout Link
- 7
Targan S R, Hanauer S B, van Deventer S J. et al .
A short-term study of chimeric monoclonal antibody cA2 to
tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease
cA2 Study Group.
N Engl J Med.
1997;
337 (15)
1029-1035 (Ib)
Reference Ris Wihthout Link
- 8
Schreiber S, Campieri M, Colombel J F. et al .
Use of anti-tumour necrosis factor agents in inflammatory
bowel disease. European guidelines for 2001-2003.
Int J Colorectal Dis.
2001;
16 (1) 1-11; discussion 12-13 (IV)
Reference Ris Wihthout Link
- 9
Keane J, Gershon S, Wise R P. et al .
Tuberculosis associated with infliximab, a tumor necrosis
factor alpha- neutralizing agent.
N Engl J Med.
2001;
345 (15)
1098-1104 (III)
Reference Ris Wihthout Link
- 10
Markowitz J, Grancher K, Kohn N. et al .
A multicenter trial of 6-mercaptopurine and prednisone in
children with newly diagnosed Crohn’s disease.
Gastroenterology.
2000;
119 (4)
895-902 (Ib)
Reference Ris Wihthout Link
- 11
Sandborn W J, Tremaine W J, Wolf D C. et al .
Lack of effect of intravenous administration on time to
respond to azathioprine for steroid-treated Crohn’s disease. North
American Azathioprine Study Group.
Gastroenterology.
1999;
117 (3)
527-535 (Ib)
Reference Ris Wihthout Link
- 12
Boulton-Jones J R, Pritchard K, Mahmoud A A.
The use of 6-mercaptopurine in patients with inflammatory
bowel disease after failure of azathioprine therapy.
Aliment Pharmacol Ther.
2000;
14 (12)
1561-1565 (IV)
Reference Ris Wihthout Link
- 13
Armstrong V W, Oellerich M.
New developments in the immunosuppressive drug monitoring of
cyclosporine, tacrolimus, and azathioprine.
Clin Biochem.
2001;
34 (1)
9-16 (IV)
Reference Ris Wihthout Link
- 14
Bouhnik Y, Lemann M, Mary J Y. et al .
Long-term follow-up of patients with Crohn’s disease
treated with azathioprine or 6-mercaptopurine.
Lancet.
1996;
347 (8996)
215-219 (IV)
Reference Ris Wihthout Link
- 15
Ramsey-Goldman R, Mientus J M, Kutzer J E. et al .
Pregnancy outcome in women with systemic lupus erythematosus
treated with immunosuppressive drugs.
J Rheumatol.
1993;
20 (7)
1152-1157 (IIb)
Reference Ris Wihthout Link
- 16
Rajapakse R O, Korelitz B I, Zlatanic J. et al .
Outcome of pregnancies when fathers are treated with
6-mercaptopurine for inflammatory bowel disease.
Am J Gastroenterol.
2000;
95 (3)
684-688 (III)
Reference Ris Wihthout Link
- 17
Kremer J M, Alarcon G S, Lightfoot R W Jr. et al .
Methotrexate for rheumatoid arthritis. Suggested guidelines
for monitoring liver toxicity. American College of Rheumatology.
Arthritis Rheum.
1994;
37 (3)
316-328 (IV)
Reference Ris Wihthout Link
- 18
Erickson A R, Reddy V, Vogelgesang S A. et al .
Usefulness of the American College of Rheumatology
recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis
patients.
Arthritis Rheum.
1995;
38 (8)
1115-1119 (IV)
Reference Ris Wihthout Link
- 19
Alarcon G S, Kremer J M, Macaluso M. et al .
Risk factors for methotrexate-induced lung injury in patients
with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung
Study Group.
Ann Intern Med.
1997;
127 (5)
356-364 (III)
Reference Ris Wihthout Link
- 20
Arthritis Clinical Trial Archive Group Rheumatoid.
The effect of age and renal function on the efficacy and
toxicity of methotrexate in rheumatoid arthritis.
J Rheumatol.
1995;
22 (2)
218-223 (III)
Reference Ris Wihthout Link
- 21
Feagan B G, Fedorak R N, Irvine E J. et al .
A comparison of methotrexate with placebo for the maintenance
of remission in Crohn’s disease. North American Crohn’s Study Group
Investigators.
N Engl J Med.
2000;
342 (22)
1627-1632 (Ib)
Reference Ris Wihthout Link
- 22
Mack D R, Young R, Kaufman S S. et al .
Methotrexate in patients with Crohn’s disease after
6-mercaptopurine.
J Pediatr.
1998;
132 (5)
830-835 (IV)
Reference Ris Wihthout Link
- 23
Ortiz Z, Shea B, Suarez A lmazor M. et al .
Folic acid and folinic acid for reducing side effects in
patients receiving methotrexate for rheumatoid arthritis.
Cochrane Database Syst Rev.
2000;
2 (Ia)
Reference Ris Wihthout Link
- 24
Neurath M F, Wanitschke R, Peters M. et al .
Randomised trial of mycophenolate mofetil versus azathioprine
for treatment of chronic active Crohn’s disease.
Gut.
1999;
44 (5)
625-628 (Ib)
Reference Ris Wihthout Link
- 25
Fellermann K, Steffen M, Stein J. et al .
Mycophenolate mofetil: lack of efficacy in chronic active
inflammatory bowel disease.
Aliment Pharmacol Ther.
2000;
14 (2)
171-176 (IV)
Reference Ris Wihthout Link
- 26
Hassard P V, Vasiliauskas E A, Kam L Y. et al .
Efficacy of mycophenolate mofetil in patients failing
6-mercaptopurine or azathioprine therapy for Crohn’s disease.
Inflamm Bowel Dis.
2000;
6 (1)
16-20 (IV)
Reference Ris Wihthout Link
- 27
Hyams J S, Markowitz J, Wyllie R.
Use of infliximab in the treatment of Crohn’s disease
in children and adolescents.
J Pediatr.
2000;
137 (2)
192-196 (IV)
Reference Ris Wihthout Link
- 28
Rutgeerts P, D’Haens G, Targan S. et al .
Efficacy and safety of retreatment with anti-tumor necrosis
factor antibody (infliximab) to maintain remission in Crohn’s
disease.
Gastroenterology.
1999;
117 (4)
761-769 (Ib)
Reference Ris Wihthout Link
- 29
Sandborn W J, Hanauer S B, Katz S. et al .
Etanercept for active Crohn’s disease: a randomized,
double-blind, placebo-controlled trial.
Gastroenterology.
2001;
121 (5)
1088-1094 (Ib)
Reference Ris Wihthout Link
- 30
Hanauer S B, Feagan B G, Lichtenstein G R. et al .
Maintenance infliximab therapy for the treatment of
Crohn’s disease.
Lancet.
2002;
359 (9317)
1541-1549 (Ib)
Reference Ris Wihthout Link
- 31
Stange E F, Modigliani R, Pena A S. et al .
European trial of cyclosporine in chronic active
Crohn’s disease: a 12-month study.
Gastroenterology.
1995;
109
774-782 (Ib)
Reference Ris Wihthout Link
- 32
Camma C, Giunta M, Rosselli M. et al .
Mesalamine in the maintenance treatment of Crohn’s
disease: a meta-analysis adjusted for confounding variables.
Gastroenterology.
1997;
113 (5)
1465-1473 (Ia)
Reference Ris Wihthout Link
- 33
Cottone M, Camma C.
Mesalamine and relapse prevention in Crohn’s
disease.
Gastroenterology.
2000;
119 (2)
597 (Ia)
Reference Ris Wihthout Link
- 34
Steinhart A H, Ewe K, Griffiths A M. et al .
Corticosteroids for maintaining remission of Crohn’s
disease (Cochrane Review).
Cochrane Database Syst Rev.
2001;
3 (Ia)
Reference Ris Wihthout Link
- 35
Simms L, Steinhart A H.
Budesonide for maintenance of remission in Crohn’s
disease.
Cochrane Database Syst Rev.
2001;
4 (Ia)
Reference Ris Wihthout Link
- 36
Rutgeerts P, Hiele M, Geboes K. et al .
Controlled trial of metronidazole treatment for prevention of
Crohn’s recurrence after ileal resection.
Gastroenterology.
1995;
108 (6)
1617 (Ib)
Reference Ris Wihthout Link